Fatty liver medical therapy: Difference between revisions
mNo edit summary |
|||
| Line 7: | Line 7: | ||
==Overview== | ==Overview== | ||
The treatment of fatty liver depends on what is causing it, and generally, treating the underlying cause will reverse the process of steatosis if implemented at early stage. Recent studies suggest that [[diet (nutrition)|diet]], [[exercise]], and especially [[anti-diabetic drug|antiglycemic drug]]s may alter the course of the disease. A [[randomized controlled trial]] found that [[pioglitazone]] led to metabolic and histologic improvement in subjects with nonalcoholic steatohepatitis.<ref name="pmid17135584">{{cite journal |author=Belfort R, Harrison SA, Brown K, ''et al'' |title=A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis |journal=N. Engl. J. Med. |volume=355 |issue=22 |pages=2297–307 |year=2006 |pmid=17135584 |doi=10.1056/NEJMoa060326}}</ref> | The treatment of fatty liver depends on what is causing it, and generally, treating the underlying cause will reverse the process of steatosis if implemented at early stage. Recent studies suggest that [[diet (nutrition)|diet]], [[exercise]], and especially [[anti-diabetic drug|antiglycemic drug]]s may alter the course of the disease. A [[randomized controlled trial]] found that [[pioglitazone]] led to metabolic and histologic improvement in subjects with nonalcoholic steatohepatitis.<ref name="pmid17135584">{{cite journal |author=Belfort R, Harrison SA, Brown K, ''et al'' |title=A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis |journal=N. Engl. J. Med. |volume=355 |issue=22 |pages=2297–307 |year=2006 |pmid=17135584 |doi=10.1056/NEJMoa060326}}</ref> | ||
Elderly may not benefit from treatment<ref name="pmid35753042">{{cite journal| author=van Kleef LA, Sonneveld MJ, Kavousi M, Ikram MA, de Man RA, de Knegt RJ| title=Fatty liver disease is not associated with increased mortality in the elderly: A prospective cohort study. | journal=Hepatology | year= 2022 | volume= | issue= | pages= | pmid=35753042 | doi=10.1002/hep.32635 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=35753042 }} </ref>. | |||
==Medical Therapy== | ==Medical Therapy== | ||
Revision as of 03:18, 22 July 2022
|
Fatty Liver Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Fatty liver medical therapy On the Web |
|
American Roentgen Ray Society Images of Fatty liver medical therapy |
|
Risk calculators and risk factors for Fatty liver medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Overview
The treatment of fatty liver depends on what is causing it, and generally, treating the underlying cause will reverse the process of steatosis if implemented at early stage. Recent studies suggest that diet, exercise, and especially antiglycemic drugs may alter the course of the disease. A randomized controlled trial found that pioglitazone led to metabolic and histologic improvement in subjects with nonalcoholic steatohepatitis.[1]
Elderly may not benefit from treatment[2].
Medical Therapy
References
- ↑ Belfort R, Harrison SA, Brown K; et al. (2006). "A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis". N. Engl. J. Med. 355 (22): 2297–307. doi:10.1056/NEJMoa060326. PMID 17135584.
- ↑ van Kleef LA, Sonneveld MJ, Kavousi M, Ikram MA, de Man RA, de Knegt RJ (2022). "Fatty liver disease is not associated with increased mortality in the elderly: A prospective cohort study". Hepatology. doi:10.1002/hep.32635. PMID 35753042 Check
|pmid=value (help).